Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Voiced support for HR 2182, The Generativng Antibiotic Incentives Now ("GAIN") Act. The legislation provides incentives for the development of infectious disease products. Voiced opposition to HR 3699, the Research Works Act. Voiced support for HR 1862, the Regenerative Medicine Promotion Act. The legislation encourages private investment in R&D, and it enables accelerated approval for regenerative medicine products. Voiced opposition to HR 3433, the Grant Reform and New Transparency Act of 2011 (GRANT ACT). The legislation requires certain standards in the award of federal grants, and for other purposes. Voiced opposition over the IPAB. Voiced opposition over proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides onology products for administration in physicians offices.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced support for HR4953, the Qualifying renewable chemical production tax credit Act of 2012
-Voiced support for the FDA User Fee Reauthorization -Voiced Support for the "Breakthroughs" provision included in the FDA User Fee Reauthorization -Voiced support for de novo process changes in the user fee package -Voiced support for GAIN within the FDA user fee package
Source: Senate LDA
Voiced support for HR 2182, The Generativng Antibiotic Incentives Now ("GAIN") Act. The legislation provides incentives for the development of infectious disease products. Voiced opposition to HR 3699, the Research Works Act. Voiced support for HR 1862, the Regenerative Medicine Promotion Act. The legislation encourages private investment in R&D, and it enables accelerated approval for regenerative medicine products. Voiced opposition to HR 3433, the Grant Reform and New Transparency Act of 2011 (GRANT ACT). The legislation requires certain standards in the award of federal grants, and for other purposes. Voiced opposition over the IPAB. Voiced opposition over proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides onology products for administration in physicians offices.
Voiced support for HR 2182, The Generativng Antibiotic Incentives Now ("GAIN") Act. The legislation provides incentives for the development of infectious disease products. Voiced opposition to HR 3699, the Research Works Act. Voiced support for HR 1862, the Regenerative Medicine Promotion Act. The legislation encourages private investment in R&D, and it enables accelerated approval for regenerative medicine products. Voiced opposition to HR 3433, the Grant Reform and New Transparency Act of 2011 (GRANT ACT). The legislation requires certain standards in the award of federal grants, and for other purposes. Voiced opposition over the IPAB. Voiced opposition over proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides onology products for administration in physicians offices.
Voiced support for HR 2182, The Generativng Antibiotic Incentives Now ("GAIN") Act. The legislation provides incentives for the development of infectious disease products. Voiced opposition to HR 3699, the Research Works Act. Voiced support for HR 1862, the Regenerative Medicine Promotion Act. The legislation encourages private investment in R&D, and it enables accelerated approval for regenerative medicine products. Voiced opposition to HR 3433, the Grant Reform and New Transparency Act of 2011 (GRANT ACT). The legislation requires certain standards in the award of federal grants, and for other purposes. Voiced opposition over the IPAB. Voiced opposition over proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides onology products for administration in physicians offices.
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced support for HR4953, the Qualifying renewable chemical production tax credit Act of 2012
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced Support for HR4953, the Qualifying Renewable Chemical Production Tax Credit Act of 2012
Qualifying Renewable Chemical Production Tax Credit Act of 2012
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced Support for HR4953, the Qualifying Renewable Chemical Production Tax Credit Act of 2012
Qualifying Renewable Chemical Production Tax Credit Act of 2012
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced support for HR4953, the Qualifying renewable chemical production tax credit Act of 2012
Support for HR 1862, the Regenerative Medicine Promotion Act.
Qualifying Therapeutic Discovery Project Tax Credit Extension Act of 2011
Support Medical Device Excise Tax Repeal Efforts Support HR 1988, the Theraputic Tax Credit Extension Act of 2011 Support HR 2632, the Life Science Jobs and Investment Act
Discussed concerns over the impact medical device and drug FDA regulation has on innovation, jobs, patients and the economy. Addressed changes to 510K process and concerns over an increasingly unpredictable regulatory system. Adressed concerns over lack of effective communication between FDA and industry, as well as administrative issues such as concerns over the FDA's access to training and education on the newest technologies. Addressed concerns over proposed new limitations on the scope of RUO and IUO products. Discussed concern that the proposed restrictions would negitively impact the practice of developing and validating clinical tests using RUO and IUO components, and would significantly change the way manufacturers can promote and sell their products, and in so doing irreparably harm innovation in this area. Addressed BIOCOM's support for a 12 year data exclusivity period for biologic products and our strong opposition to any proposed reduction to the 12 year data exclusivity period. Addressed opposition to the IOM's recommendation to dismantle the FDA 510K process. Support HR 2182, The Generating Antibiotic Incentives Now ("GAIN") Act.
Support Medical Device Excise Tax Repeal Efforts Support HR 1988, the Theraputic Tax Credit Extension Act of 2011 Support HR 2632, the Life Science Jobs and Investment Act
Voiced support HR 2632, the Life Science Jobs and Investment Act
H.R.734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes. SUMMARY: Repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. Rescinds $39 billion of appropriated but unobligated discretionary funds. Exempts unobligated funds of the DOD and VA. HR 436: Protect Medical Innovation Act of 2011 SUMMERY: Protect Medical Innovation Act of 2011 - Amends the Internal Revenue Code to repeal the excise tax on medical devices. BIOCOM has been deeply concerned about the negative impact the 2.3 percent ($20 billion) tax will have on employment and the economy in the San Diego region and supports repealing the tax on medical device companies.
Medical Device Excise Tax Repeal Bills BIOCOM supports repealing the 2.3 ($20 billion) tax on medical device companies. HR 734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes Summery: Repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. Rescinds $39 billion of appropriated but unobligated discretionary funds. Exempts funds of the DOD and VA. HR 436: Protect Medical Innovation Act of 2011 Summery: Amends the Internal Reveue Code to repeal the excise tax on medical devices. Therapeutic Discovery Project ("TDP") Program BIOCOM supports an extension of the TDP, which expired at the end of 2010.
H.R.734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes. This bill repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. HR 436: Protect Medical Innovation Act of 2011 - Amends the Internal Revenue Code to repeal the excise tax on medical devices.
To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes.
H.R.734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes. SUMMARY: Repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. Rescinds $39 billion of appropriated but unobligated discretionary funds. Exempts unobligated funds of the DOD and VA. HR 436: Protect Medical Innovation Act of 2011 SUMMERY: Protect Medical Innovation Act of 2011 - Amends the Internal Revenue Code to repeal the excise tax on medical devices. BIOCOM has been deeply concerned about the negative impact the 2.3 percent ($20 billion) tax will have on employment and the economy in the San Diego region and supports repealing the tax on medical device companies.
To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes.
Medical Device Excise Tax Repeal Bills BIOCOM supports repealing the 2.3 ($20 billion) tax on medical device companies. HR 734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes Summery: Repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. Rescinds $39 billion of appropriated but unobligated discretionary funds. Exempts funds of the DOD and VA. HR 436: Protect Medical Innovation Act of 2011 Summery: Amends the Internal Reveue Code to repeal the excise tax on medical devices. Therapeutic Discovery Project ("TDP") Program BIOCOM supports an extension of the TDP, which expired at the end of 2010.
H.R.734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes. This bill repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. HR 436: Protect Medical Innovation Act of 2011 - Amends the Internal Revenue Code to repeal the excise tax on medical devices.
Voiced Support for the Energy title programs within the 2002 farm bills to be included in the new Farm Bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced Support for HR4953, the Qualifying Renewable Chemical Production Tax Credit Act of 2012
Voiced Support for the FDA User Fee Reauthorization. Voiced Support for the "Breakthroughs" provision included in the FDA User Fee Reauthorization. Voiced Support for the de novo process changes in FDA User Fee Reauthorization. Voiced Support for GAIN within the FDA User Fee package
Voiced Support for the Energy Title programs within the 2002 and 2008 farm bills to be included in the new Farm Bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Voiced support for Medical Device Excise Tax Repeal Efforts.
Voiced Support for the Energy Title programs within the 2002 and 2008 farm bills to be included in the Farm Bill.
Voiced support for HR 2182, The Generativng Antibiotic Incentives Now ("GAIN") Act. The legislation provides incentives for the development of infectious disease products. Voiced opposition to HR 3699, the Research Works Act. Voiced support for HR 1862, the Regenerative Medicine Promotion Act. The legislation encourages private investment in R&D, and it enables accelerated approval for regenerative medicine products. Voiced opposition to HR 3433, the Grant Reform and New Transparency Act of 2011 (GRANT ACT). The legislation requires certain standards in the award of federal grants, and for other purposes. Voiced opposition over the IPAB. Voiced opposition over proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides onology products for administration in physicians offices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Address issues related to patent reform legislation implementation, including support for fee retention
Addressed concerns over Mobile Medical Applications Addressed concerns over lack of effective communication between FDA and industry, as well as administrative issues such as concerns over the FDA's access to training and education on the newest technologies Addressed BIOCOM's support for a 12 year data exclusivity period for biologic products and our strong opposition to any proposed reduction to the 12 year data exclusivity period Discussed the Medical Device Regulatory Improvement Act 10 House Bills which include the following: oH.R. 3209, Premarket Predictability Act of 2011 oH.R. 3203, Novel Device Regulatory Relief Act of 2011 oH.R. 3230, Keeping America Competitive through Harmonization Act oH.R. 3205, FDA Renewing Efficiency from Outside Review Management Act oH.R. 3211, Humanitarian Device Reform Act oH.R. 3208, Patients Come First Act oH.R 3206,Cultivating Scientific Expertise to Foster Innovation Act oH.R. 3214, Food and Drug Administration Mission Reform Act oH.R. 3207, Modernizing Laboratory Test Standards for Patients Act oH.R. 3204, Guidance Accountability and Transparency Act
Opposed proposed cuts to Part B, which provides oncology products for administration in physicians offices
Voiced support HR 2632, the Life Science Jobs and Investment Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)
Support for HR 1862, the Regenerative Medicine Promotion Act.
Support Medical Device Excise Tax Repeal Efforts Support HR 1988, the Theraputic Tax Credit Extension Act of 2011 Support HR 2632, the Life Science Jobs and Investment Act
Addressed opposition over the Independent Payment Advisory Board ("IPAB"). Expressed concern over the IPAB which is an unelected body that could institute broad changes to Medicare with no Congressional input or oversight. Opposed proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides oncology products for administration in physicians offices.
Discussed concerns over the impact medical device and drug FDA regulation has on innovation, jobs, patients and the economy. Addressed changes to 510K process and concerns over an increasingly unpredictable regulatory system. Adressed concerns over lack of effective communication between FDA and industry, as well as administrative issues such as concerns over the FDA's access to training and education on the newest technologies. Addressed concerns over proposed new limitations on the scope of RUO and IUO products. Discussed concern that the proposed restrictions would negitively impact the practice of developing and validating clinical tests using RUO and IUO components, and would significantly change the way manufacturers can promote and sell their products, and in so doing irreparably harm innovation in this area. Addressed BIOCOM's support for a 12 year data exclusivity period for biologic products and our strong opposition to any proposed reduction to the 12 year data exclusivity period. Addressed opposition to the IOM's recommendation to dismantle the FDA 510K process. Support HR 2182, The Generating Antibiotic Incentives Now ("GAIN") Act.
Address issues related to HR/1249 and S 23, the patent reform legislation, including support for fee retention, and putting an end to qui tam complaints for alleged false markings.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Medical Device Excise Tax Repeal Bills BIOCOM supports repealing the 2.3 ($20 billion) tax on medical device companies. HR 734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes Summery: Repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. Rescinds $39 billion of appropriated but unobligated discretionary funds. Exempts funds of the DOD and VA. HR 436: Protect Medical Innovation Act of 2011 Summery: Amends the Internal Reveue Code to repeal the excise tax on medical devices. Therapeutic Discovery Project ("TDP") Program BIOCOM supports an extension of the TDP, which expired at the end of 2010.
The Small Business Innovation Research Program ("SBIR") BIOCOM supported BIR Reauthorization before the program was set to expire on May 31
Educational meetings associated with the biofuels industry, scientific research, and workforce development in San Diego.
H.R.734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes. SUMMARY: Repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. Rescinds $39 billion of appropriated but unobligated discretionary funds. Exempts unobligated funds of the DOD and VA. HR 436: Protect Medical Innovation Act of 2011 SUMMERY: Protect Medical Innovation Act of 2011 - Amends the Internal Revenue Code to repeal the excise tax on medical devices. BIOCOM has been deeply concerned about the negative impact the 2.3 percent ($20 billion) tax will have on employment and the economy in the San Diego region and supports repealing the tax on medical device companies.
H.R.734: To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes. This bill repeals the provision of the Internal Revenue Code, added by the Health Care and Education Reconciliation Act of 2010, that imposes an excise tax on medical devices. HR 436: Protect Medical Innovation Act of 2011 - Amends the Internal Revenue Code to repeal the excise tax on medical devices.
Filing targets: HOUSE OF REPRESENTATIVES
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
Repeal of Independent Payment Advisory Board ("IPAB") BIOCOM supports the repeal of the IPAB which was created with the passage of The Patient Protection and Affordable Care Act ("PPACA").
H.R. 1249: Patent Reform BIOCOM supports establishing the principle of fee retention with respect to fees collected by the USPTO. BIOCOM also supports the proposed modifications to post-grant opposition; BIOCOM supports the proposed supplemental examination procedure included in the Managers Amendment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 23: America Invents Act SUMMERY: Amends federal patent law. BIOCOM has a keen interest in potential changes to the US patent system which may substantially increase the cost of obtaining patents, increase the risk of challenge to the resulting patents, and consequently reduce the ability of small companies which do so much of the innovative research in this country. BIOCOM is pleased with S 23. BIOCOM supports the proposed Supplemental examination procedure for presenting to the United States Patent and Trademark Office (USPTO) potentially relevant prior art which was not before the Patent Examiner during the initial prosecution of the patent at issue as a way to begin to address the scourge of charges of inequitable conduct during patent litigation. BIOCOM also supports the proposed modifications to post-grant opposition; for example, the proposed reduction of the window for challenging recently issued US Patents to nine-months would conform US practice with the established practice of other countries which have a postgrant opposition system. In addition, the enhanced threshold for instituting a post-grant opposition proceeding will go a long way towards addressing the concern with abusive use of post-grant oppositions. Additional provisions of S. 23 which put an end to qui tam complaints for alleged false marking, reduce the ability of patent challengers to rely upon an alleged failure to satisfy the best mode requirement, provide the PTO with fee-setting authority and repeal the Baldwin rule are also welcome additions, which BIOCOM supports.
Filing targets: HOUSE OF REPRESENTATIVES
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues